Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

18F-Fluoroethyl-L Tyrosine Positron Emission Tomography Radiomics in the Differentiation of Treatment-Related Changes from Disease Progression in Patients with Glioblastoma

B. Manzarbeitia-Arroba, M. Hodolic, R. Pichler, O. Osipova, ÁM. Soriano-Castrejón, AM. García-Vicente

. 2023 ; 16 (1) : . [pub] 20231230

Status not-indexed Language English Country Switzerland

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc24006124

The follow-up of glioma patients after therapeutic intervention remains a challenging topic, as therapy-related changes can emulate true progression in contrast-enhanced magnetic resonance imaging. 18F-fluoroethyl-tyrosine (18F-FET) is a radiopharmaceutical that accumulates in glioma cells due to an increased expression of L-amino acid transporters and, contrary to gadolinium, does not depend on blood-brain barrier disruption to reach tumoral cells. It has demonstrated a high diagnostic value in the differentiation of tumoral viability and pseudoprogression or any other therapy-related changes, especially when combining traditional visual analysis with modern radiomics. In this review, we aim to cover the potential role of 18F-FET positron emission tomography in everyday clinical practice when applied to the follow-up of patients after the first therapeutical intervention, early response evaluation, and the differential diagnosis between therapy-related changes and progression.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24006124
003      
CZ-PrNML
005      
20240412130911.0
007      
ta
008      
240405s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers16010195 $2 doi
035    __
$a (PubMed)38201621
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Manzarbeitia-Arroba, Begoña $u Nuclear Medicine Department, University Hospital of Toledo, 45007 Toledo, Spain
245    10
$a 18F-Fluoroethyl-L Tyrosine Positron Emission Tomography Radiomics in the Differentiation of Treatment-Related Changes from Disease Progression in Patients with Glioblastoma / $c B. Manzarbeitia-Arroba, M. Hodolic, R. Pichler, O. Osipova, ÁM. Soriano-Castrejón, AM. García-Vicente
520    9_
$a The follow-up of glioma patients after therapeutic intervention remains a challenging topic, as therapy-related changes can emulate true progression in contrast-enhanced magnetic resonance imaging. 18F-fluoroethyl-tyrosine (18F-FET) is a radiopharmaceutical that accumulates in glioma cells due to an increased expression of L-amino acid transporters and, contrary to gadolinium, does not depend on blood-brain barrier disruption to reach tumoral cells. It has demonstrated a high diagnostic value in the differentiation of tumoral viability and pseudoprogression or any other therapy-related changes, especially when combining traditional visual analysis with modern radiomics. In this review, we aim to cover the potential role of 18F-FET positron emission tomography in everyday clinical practice when applied to the follow-up of patients after the first therapeutical intervention, early response evaluation, and the differential diagnosis between therapy-related changes and progression.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Hodolic, Marina $u Nuclear Medicine Department, Faculty of Medicine and Dentistry, Palacky University, 779 00 Olomouc, Czech Republic
700    1_
$a Pichler, Robert $u Institute of Nuclear Medicine Kepler University Hospital-Neuromed Campus, 4020 Linz, Austria
700    1_
$a Osipova, Olga $u Institute of Nuclear Medicine Kepler University Hospital-Neuromed Campus, 4020 Linz, Austria
700    1_
$a Soriano-Castrejón, Ángel Maria $u Nuclear Medicine Department, University Hospital of Toledo, 45007 Toledo, Spain
700    1_
$a García-Vicente, Ana María $u Nuclear Medicine Department, University Hospital of Toledo, 45007 Toledo, Spain
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 16, č. 1 (2023)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38201621 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240405 $b ABA008
991    __
$a 20240412130904 $b ABA008
999    __
$a ok $b bmc $g 2076138 $s 1215886
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 16 $c 1 $e 20231230 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
LZP    __
$a Pubmed-20240405

Find record

Citation metrics

Archiving options